7 November 2017 | Geneva – WHO is recommending that farmers and the food industry stop using antibiotics routinely to promote growth and prevent disease in healthy animals.
The new WHO recommendations aim to help preserve the effectiveness of antibiotics that are important for human medicine by reducing their unnecessary use in animals. In some countries, approximately 80% of total consumption of medically important antibiotics is in the animal sector, largely for growth promotion in healthy animals.
The Minister for Health Simon Harris TD today announced that he is convening the National Public Health Emergency Team, as a public health response to the CPE/CRE superbug. Carbapenemase Producing Enterobacteriaceae (CPE) has been declared as a public health emergency, so that it is managed in line with the Public Health Plans which have been previously put in place for influenza.
CPE (also referred to as Carbapenem Resistant Enterobacteriaceae (CRE)) is the newest in a long line of ‘superbugs’ or bacteria that are hard to kill with antibiotics and are a particular problem in hospital settings.
National Public Health Emergency Team as a public health response to CPE superbug
Ireland’s National Action Plan on Antimicrobial Resistance 2017-2020 (iNAP) recognises the urgent and growing problem of antimicrobial resistance for human health worldwide. It aims to implement policies and actions to prevent, monitor and combat AMR across the health, agricultural and environmental sectors. Reducing the inappropriate use of antimicrobial medicines, as well as preventing the transmission of infections and disease, is vital to stop the development and spread of resistant microorganisms.
AMR National Plan
AMR Plan PDF
50 water treatment plants fail to meet EU standards
Full EPA Report
Joint Programming Initiative on Antimicrobial Resistance
At the Call to Action in Berlin on October 12-13, the JPIAMR will commit to several new initiatives and actions for 2018.
Details on JPIAMR Call to Action
20 September 2017 | Geneva – A report, Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis, launched today by WHO shows a serious lack of new antibiotics under development to combat the growing threat of antimicrobial resistance.
WHO Press Release
For Full Report Click Below (as PDF)
13th of September, 2017 – Paris, France – The European Commission, policymakers, and organisations from 28 countries meet at the French Ministry of Health in Paris to launch the European Joint Action on Antimicrobial Resistance and HealthCare-Associated Infections (EU-JAMRAI), coordinated by France (French National Institute of Health and Medical Research, Inserm, with the support of the French Ministry of Health).
The Joint Action, EU-JAMRAI, aims to bring together the participating EU member states and international organisations, institutes, universities to contribute to tackle Antimicrobial Resistance (AMR) and Healthcare-Associated Infections (HCAI). It will capitalise on existing initiatives and propose concrete steps to reduce the burden of AMR.
On the 23 and 24 November 2017, the Society for Applied Microbiology will hold its 3rd Antimicrobial Resistance Conference in Charles Darwin House, London, in collaboration with the Academy of Pharmaceutical Sciences and the Royal Society of Chemistry.
Antimicrobial resistance (AMR) is one of the most important international issues for human and animal health and the global spread of AMR threatens to negate cures for infectious disease that began with the introduction of penicillin. Systematic misuse and overuse of antibiotics in human medicine and animal husbandry have put every individual at risk. The Society for Applied Microbiology joins the Royal Society of Chemistry and the Academy of Pharmaceutical Sciences in responding to the global challenge to help tackle the AMR crisis.
The WHO Model Lists of Essential Medicines has been updated every two years since 1977.
The current versions are the 20th WHO Essential Medicines List (EML) and the 6th WHO Essential Medicines List for Children (EMLc) updated in March 2017.